Analysts Highlight BrainStorm’s Potential Growth Despite Challenges Brainstorm Cell Therapeutics has been rated "hold" by StockNews.com analysts, reflecting cautious optimism. While its stock has faced volatility, its 12-month low of $1.05 contrasts sharply with a high of $11.89. With a beta of 0.74, the stock shows lower risk compared to market averages, indicating moderate investor confidence.45